Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-resolution HLA-A*0201 subtyping using directed heteroduplex analysis.

E J Kicklighter1, K H Lee, K C Barracchini

  • 1Department of Transfusion Medicine, National Institute of Health, Bethesda, MD 20892, USA.

Journal of Immunotherapy (Hagerstown, Md. : 1997)
|May 21, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence for CD19B-CD8T cell interactions in blood and tissues from patients with GvHD.

Bone marrow transplantation·2016
Same author

Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015.

Journal of translational medicine·2016
Same author

Targeting proapoptotic protein BAD inhibits survival and self-renewal of cancer stem cells.

Cell death and differentiation·2014
Same author

Direct T cell-tumour interaction triggers TH1 phenotype activation through the modification of the mesenchymal stromal cells transcriptional programme.

British journal of cancer·2014
Same author

CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2.

British journal of cancer·2013
Same author

IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes.

British journal of cancer·2013

A new method called directed heteroduplex analysis (DHDA) effectively screens Human Leukocyte Antigen (HLA)-A*02 subtypes. This reliable technique aids in identifying specific HLA-A*02 alleles crucial for immunotherapy.

Area of Science:

  • Immunogenetics
  • Molecular Biology
  • Biotechnology

Background:

  • Human Leukocyte Antigen (HLA)-A*02 is a key target in cytotoxic T lymphocyte immunotherapy due to its high prevalence.
  • Significant functional differences exist among the at least 26 HLA-A*02 alleles, impacting T-cell recognition.
  • Accurate subtyping of HLA-A*02 is critical for effective immunotherapeutic strategies.

Purpose of the Study:

  • To develop and validate a novel method for screening Human Leukocyte Antigen (HLA)-A*02 subtypes.
  • To assess the specificity and sensitivity of directed heteroduplex analysis (DHDA) for HLA-A*02 allelic screening.
  • To expand the molecular typing capabilities for HLA laboratories.

Main Methods:

  • Developed Directed Heteroduplex Analysis (DHDA) for HLA-A*02 allelic screening.

Related Experiment Videos

  • Utilized DNA from Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines (EBV-B) representing 10 HLA-A*02 alleles.
  • Employed PCR amplification with HLA-A*02 specific primers targeting exons 2 and 3, followed by heteroduplex formation and gel analysis.
  • Validated DHDA results against sequence-specific primer (SSP) polymerase chain reaction (PCR) and DNA sequencing.

    • Main Results:

    • DHDA demonstrated high specificity and sensitivity in identifying HLA-A*02 alleles from EBV-B cell lines.
    • Identified specific probe combinations (e.g., 0205 + 0211 and 0208 + 0211) capable of differentiating HLA-A*0201 from other subtypes.
    • DHDA typing results were consistently confirmed by SSP typing and DNA sequencing for all tested samples.

    Conclusions:

    • Directed Heteroduplex Analysis (DHDA) is a reliable and promising method for HLA-A*02 subtyping.
    • This novel technique enhances the molecular typing repertoire for HLA laboratories.
    • DHDA offers a valuable tool for screening specific HLA-A*02 alleles relevant to immunotherapy.